表紙
市場調査レポート

EpiCast Report:小細胞肺がん (SCLC) - 2024年までの疫学予測

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 352144
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
EpiCast Report:小細胞肺がん (SCLC) - 2024年までの疫学予測 EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
出版日: 2016年01月01日 ページ情報: 英文 47 Pages
概要

世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本)で小細胞肺がん (SCLC) と診断された発症件数は、2014年の79,077件から、2024年には91,640件まで、年間成長率で1.59%の増加が予測されています。

当レポートでは、世界の主要7ヶ国における小細胞肺がん (SCLC) について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 小細胞肺がん (SCLC) の疫学予測
    • 診断された発症件数
    • 診断された発症件数 (年齢別)
    • 診断された発症件数 (性別)
    • 診断された発症件数 (年齢標準化)、など
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER107-15

Small Cell Lung Cancer (SCLC) is a distinct form of lung cancer that typically initially presents in the central airways before spreading to the submucosa, which leads to the narrowing of airways. SCLC is considered to be highly malignant due to its cell composition that causes faster doubling time, earlier development of metastases, and worsened prognosis when compared with other lung cancer types. SCLC is widely considered to account for 15% of all lung cancer cases, with the other lung cancer cases being predominantly caused by non-small cell lung cancer (NSCLC). SCLC is typically presented in two main stages, limited stage (LS-SCLC) and extensive stage (ES-SCLC).

GlobalData epidemiologists forecast that the diagnosed incident cases of SCLC will increase from 79,077 cases in 2014 to 91,640 cases in 2024 across the 7MM with an Annual Growth Rate (AGR) of 1.59%. The US had the highest proportion of SCLC diagnosed incident cases out of the 7MM throughout the forecast period. In 2014, there were 23,361 LS-SCLC diagnosed incident cases and 55,716 ES-SCLC diagnosed incident cases in the 7MM, accounting for 29.54% and 70.46% of the total SCLC diagnosed incident cases, respectively. Further, GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of SCLC will increase from 59,330 cases in 2014 to 71,528 cases in 2024 with an AGR of 2.06%. Out of the 7MM, Japan had the highest proportion of SCLC five-year diagnosed prevalent cases across the forecast period.

GlobalData's epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of SCLC in the 7MM is supported by age- and sex-specific incidence data obtained for the individual markets. Further, the analysis was strengthened by the use of a consistent methodology and definition of lung cancer for the diagnosed incident cases in the SCLC forecast, and using linear regression techniques when suitable. In addition, the forecast is based on age-, sex-, and market-specific historical data points obtained from the NCC, CI5plus, ITACAN, SEER, and ZfKD databases. The use of a consistent methodology across the 7MM to forecast the total diagnosed incident cases, and the five-year diagnosed prevalent cases of SCLC, allows for a meaningful comparison of the forecast incident cases and the forecast five-year prevalent cases of SCLC across the 7MM. Further, GlobalData epidemiologists provided the diagnosed incident cases of SCLC in the 7MM segmented into LS-SCLC and ES-SCLC at diagnosis.

Scope

  • The Small Cell Lung Cancer (SCLC) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of SCLC and the five-year diagnosed prevalent cases of SCLC segmented by sex, age (beginning at 18 years and ending at =85 years), and stage in these markets.
  • The SCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The Small Cell Lung Cancer (SCLC) EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SCLC market.
  • Quantify patient populations in the global SCLC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for SCLC therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Stage at Diagnosis
    • 3.3.3. Relative Survival
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for SCLC (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of SCLC
    • 3.5.2. Age-Specific Incident Cases of SCLC
    • 3.5.3. Sex-Specific Incident Cases of SCLC
    • 3.5.4. Age-Standardized Incidence of SCLC
    • 3.5.5. Stage-Specific Incident Cases of SCLC
    • 3.5.6. Five-Year Diagnosed Prevalent Cases of SCLC
    • 3.5.7. Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities Associated with SCLC
  • Table 2: 7MM, Sources Used for Diagnosed Incidence of SCLC, 2014
  • Table 3: 7MM, Sources Used for Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis
  • Table 4: 7MM, Sources Used for the Five-Year Diagnosed Prevalent Cases of LS-SCLC
  • Table 5: 7MM, Sources Used for the Five-Year Relative Survival of ES-SCLC
  • Table 6: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024
  • Table 7: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, N (Row %), 2014
  • Table 8: 7MM, Sex-Specific Diagnosed Incident Cases of SCLC, Ages ≥18 Years, N (Row %), 2014
  • Table 9: 7MM, Diagnosed Incident Cases of SCLC Segmented by Stage at Diagnosis, Ages ≥18 Years, N, 2014
  • Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024
  • Table 11: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage at Diagnosis, Ages ≥18 Years, N, 2014

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages ≥18 Years, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of SCLC, Ages ≥18 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of SCLC, Ages ≥18 Years, 2014
  • Figure 5: 7MM, Five-Year Diagnosed Prevalent Cases of SCLC, Both Sexes, Ages ≥18 Years, 2014-2024
Back to Top